Comparing Two Drug Combinations for Stem Cell Transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares two different drug combinations (BeFluBu and FluBuRux) used before a stem cell transplant from a half-matched (haploidentical) donor. The goal is to see which combination works better to prepare your body for the transplant and control your blood cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a blood cancer (like leukemia or myelodysplastic syndrome) that is in remission.
- You have a related donor (like a sibling or child) who is at least a half-match (5 out of 10 HLA markers).
- Your heart, lungs, kidneys, and liver are working well enough.
- You do not have an active infection that is not controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing two different chemotherapy regimens (with one or two alkylating agents) before a stem cell transplant for people with acute myeloid leukemia or myelodysplastic syndrome. The goal is to find which conditioning treatment is safer and more effective.
This trial tests a combination of two drugs (SHR2554 and azacitidine) given before a stem cell transplant for people with high-risk or relapsed leukemia or MDS. The goal is to see if this approach can help make the transplant more effective and reduce the chance of the disease coming back.
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests a stronger chemo and radiation plan before a stem cell transplant for people with myelodysplastic syndrome (a blood disorder) or acute myeloid leukemia (a blood cancer). The goal is to help the transplant work better and reduce the chance of the disease coming back.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.